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Volume 53, Number 5 Mastracci 1437gitation across the aortic valve. Yet, the retrograde ap-
proach can also cause temporary mitral valve insufficiency.
Intraoperative echocardiography shows a direct relation-
ship between blood pressure, duration of aortic insuffi-
ciency, and volume overload of the left ventricle. Partial
right atrial inflow occlusion could therefore be the safest
way to permit accurate graft deployment.
PROBLEMS AND TECHNICAL PITFALLS
This is only a small study with an inhomogeneous
group of patients. Several issues must be addressed before a
routine use can be advocated outside of studies. There
should be dedicated grafts for ascending aneurysms and for
acute dissections without bare springs. The problem of
cerebral emboli must be solved.11 Temporary cross clamp-
ing and cerebral perfusion with an extracorporeal pump is
relatively safe but further increases the invasiveness of the
procedure. We did not have any evidence of emboli in the
carotid arteries. Precise deployment of the graft adjacent to
the coronary arteries is essential in aneurysm patients. In
most cases, there is a landing zone of a fewmillimeters only,
deployment too distal from the sinotubular junction results
in kinking of the graft and a subsequent type I leak.
We do not have long-term follow-up data in these few
cases. A mean follow-up of 9 months only, although with-
out any changes in graft performance, is too short to permit
any conclusions about the long-term durability of this
technique. The hemodynamic consequences are unknown.
Theoretically, the elasticity of the ascending aorta should
decrease after graft deployment. It is unknownwhether this
affects blood pressure regulation, coronary artery perfu-
sion, or the stability of the endograft. Reduced aortic wall
elasticity can be associated with increased aortic regurgita-
tion and left ventricular hypertrophy.12 Ascending aortic
aneurysms already have reduced aortic wall elasticity asso-
ciated with various degrees of aortic regurgitation and
ventricular hypertrophy. We can only assume that deploy-
ment of a stent graft will not cause further deterioration of
cardiac function. One of the objectives of future studies
must be the measurement of the circumferential aortic
strain and deformation using cardiac gated image data.
CONCLUSIONS
Stent grafting of the ascending aorta is technically
feasible but should be reserved for selected high-risk pa-
tients only, preferably in centers where vascular specialists
cooperate closely with interventional cardiologists. Cardiac S
the importance of respecting the long-held truths of aortic surgery.
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surgery with cardiopulmonary bypass and, if necessary,
eep hypothermia is still the gold standard when treating
scending aortic aneurysm, although still associated with
ignificant morbidity and mortality.13 Stent graft exclusion
f more advanced and complex ascending aortic aneurysms
hould be reserved for high-risk patients only in centers
ith the necessary skills to perform transvalvular cardiac
rocedures. This may change in the future when more
edicated grafts become available.
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Surgery, many say, is like riding a bike. Regardless of the
challenge of the terrain, the sophistication of the vehicle, or the
time passed since the cyclists’ last journey, basic principles prevail.
The advent of endovascular technology has given the field of
vascular surgery a lesson in self-directed learning and has taught use are, in many cases, experienced cyclists with constantly evolv-
ng bicycles.
With calculated steps over 20 years, a primitive endovascular
raft for an infrarenal aneurysm1 has evolved into branched and
enestrated technology to treat thoracoabdominal disease, while
taying true to surgical principles. The natural progression of this
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May 20111438 Mastraccievolution is extension into the arch and ascending aorta. Although
many groups will claim this territory as “conquered,” a truly
endovascular solution has only recently come within reach after 20
years into the development of devices and delivery systems.
Modern understanding of the natural behavior of the arch and
ascending aorta has also evolved, and most would agree it is
different from distal segments in both its native and pathologic
state. From the outset, creating a multidisciplinary team, including
cardiologists and cardiothoracic surgeons, to participate in the
evaluation and management of technology in this new territory
would seem prudent to its success.
Current iterations of arch and ascending devices have been
built on the case-by-case experience of many surgeons. The heter-
ogenous body of literature that has resulted is not amenable to
statistical interrogation but is shaping future devices. The lessons
learned from each deployment have shaped the collective knowl-
edge base: in early-stage device development, the caveats and
modes of failure—almost more than the successes—become the
valuable learning points.
The authors present their experience with ascending aortic
stent grafts. Their mandate was appropriate for new technology: to
treat patients with no surgical option who had no characteristics
that might lead to predictable failure (ie, connective tissue disor-
ders, aortic valve incompetence, stenosis, or concomitant coronary
artery disease). The authors gain experience that leads to a change
in operative procedure in midcourse and describe important cave-
ats about proximal extension of the delivery system to avoid
ventricular rupture, as well as their methods for dealing with device
failure. They describe challenges of preoperative device sizing and
the limitations of current devices. The short-term outcomes they
report, with only one death and one stroke, seem favorable, but
time and ongoing surveillance will be the true test of durability of
their approach.
The cautionary tale in this unfinished story is that basic prin-
ciples have been dismissed. The practice of landing endografts in
suboptimal landing zones, without ensuring both sealing and
fixation are present at the index procedure may be a risky practice.
Extrapolating experience from the infrarenal aorta, this does not
lead to stable endovascular repair. Many vascular surgeons are noweeing patients with suboptimal infrarenal landing zones and per-
istent type I endoleaks after placement of early generation devices
ho require open or fenestrated conversion. The 3-dimensional
ovements of the ascending aorta throughout the cardiac cycle
ake it a more dynamic region for landing than any other distal
erritory. Accepting suboptimal conditions and then coiling the
urrounding aneurysm sac should be considered with caution, and
he long-term results are certainly needed.
In addition, the aortic valve, root, and coronary arteries should
e viewed as proximal constraints in both structure and function,
nd deployment should be varied depending on their condition. It
eems intuitive that devices, delivery systems, or methods of de-
loyment that cause trauma to the valvular apparatus are unlikely
o add long-term benefit, even if we see short-term success. Fur-
her investigation is warranted into techniques that place traumatic
orces on valve leaflets, such as deploying the endograft into the
alve and pulling it back into position, making follow-up imaging
f valvular function as crucial as surveillance of the aneurysm repair
tself. Advances in the treatment of new territories should closely
arallel advances in imaging and evolving paradigms for long-term
ollow-up.
As we struggle to develop new devices to treat the diseases
resented in the arch and ascending aorta, experience will evolve
ur current tools to a form that may become standard of care. It is
mportant to push the limits and challenge existing paradigms to
dvance knowledge, but it must be done with a degree of caution.
edicated grafts for ascending aortic aneurysms and dissections
eed to be developed. Until that time, however, early technology
or the treatment of life-threatening ascending pathology in pa-
ients with no other options may place the vascular intervention-
list in a similar quandary as the fledgling cyclist cautiously eyeing
hat first pair of spandex shorts: Just because we can, doesn’t always
ean we should.
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